Back to Archived News
Biomoda Awarded Patent Securing Assay Formulation and Use
Tuesday, March 02, 2010
Albuquerque, NM -- Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, "Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation.
"This new patent further strengthens and secures Biomoda’s market position for early cancer detection," said John Cousins, Biomoda’s President. "It reflects the continuing and successful research and development that is an essential part of our Company."
Biomoda's patented cancer and pre-cancer cell based diagnostic assay is trademarked under the name CyPath®. Patent 7,670,799 together with Biomoda’s U.S. patents 6,838,248, entitled "Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" and 7,384,764, entitled "Methods for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" protect the method of detecting cancerous conditions and prognosing responses to cancer therapy with TCPP.
The TCPP platform is the foundation for CyPath®, an in-vitro test for the detection of early-stage lung cancer that currently is completing Phase II clinical trials. Study volunteers have provided deep-lung sputum samples to be screened for cancer with the CyPath® assay in the Biomoda laboratory. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy.
Biomoda is seeking Food and Drug Administration (FDA) approval of CyPath®, its cytology-based screening technology as a Class III medical device. Multisite Phase III trials, the final step before FDA approval, are scheduled to begin in 2010.
About Biomoda
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this document and are subject to change without notice.
Back to Archived News
